DS3610 / Daiichi Sankyo - LARVOL DELTA

A phase 1, first-in-human study of DS3610, a stimulator of interferon genes (STING) agonist antibody-drug conjugate (ADC), in patients with advanced/metastatic solid tumors. (ASCO 2026) - P1 | "Exploratory endpoints include evaluating the efficacy of DS3610 and identifying biomarkers that may be associated with clinical benefit. Enrollment is ongoing."

ADC • Clinical • First-in-human • IO biomarker • Metastases • P1 data • Biliary Cancer • Biliary Tract Cancer • Colorectal Cancer • Esophageal Cancer • Gastric Cancer • Genito-urinary Cancer • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Renal Cell Carcinoma • Solid Tumor • Urothelial Cancer • Uterine Cancer • STING

Trials-in-Progress Presentations Highlight Breakthrough Generating Technology Focus (Businesswire) - "Trials-in-progress poster presentations featuring three potential new medicines include DS3610 (TPS3159), a STING (stimulator of interferon genes) ADC, in patients with advanced or metastatic solid tumors; DS5361 (TPS2680), a small-molecule, nonsense-mediated mRNA decay inhibitor, in patients with advanced or metastatic solid tumors; and, DS9051 (TPS3179), a novel targeted protein degradation molecule, in patients with advanced or metastatic adrenocortical carcinoma or metastatic castration-resistant prostate cancer."

Trial status • Adrenal Cortex Carcinoma • Castration-Resistant Prostate Cancer

DS3610-071: First-in-Human Trial of DS3610a in Participants with Advanced Solid Tumors (clinicaltrialsregister.eu) - P1 | N=12 | Not yet recruiting | Sponsor: Daiichi Sankyo Inc.

First-in-human • New P1 trial • Oncology • Solid Tumor

A Study of DS3610a in Participants With Advanced Solid Tumor (clinicaltrials.gov) - P1 | N=70 | Recruiting | Sponsor: Daiichi Sankyo | Not yet recruiting ➔ Recruiting

Enrollment open • First-in-human • Solid Tumor

DS3610 Enters Clinical Development in Patients with Advanced Solid Tumors as First STING Agonist ADC in Industry-Leading ADC Portfolio of Daiichi Sankyo (Businesswire) - "The first patient has been dosed in a first-in-human phase 1 trial evaluating DS3610 in patients with advanced, metastatic or unresectable solid tumors."

First-in-human • P1 data • Solid Tumor

DS-3610: Initiation of P1 trial (NCT07159126) for solid tumors in H2 FY2025 (Daiichi Sankyo) - Q2 FY2025 Results

Trial initiation date • Oncology • Solid Tumor

A Study of DS3610a in Participants With Advanced Solid Tumor (clinicaltrials.gov) - P1 | N=70 | Not yet recruiting | Sponsor: Daiichi Sankyo

New P1 trial • Solid Tumor